Investigation of the therapeutic interaction of mesenchymal stem cells with glioblastoma stem-like cells and its biological mechanism

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K19996
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Neurosurgery
• Research Institution: Kanazawa University
• Principal Investigator: Pyko Ilya 金沢大学, がん進展制御研究所, 博士研究員 (00731853)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: glioblastoma / temozolomide / mesenchymal stem cells / GSK3β

Outline of Final Research Achievements

We investigated whether mesenchymal stem cells (MSCs) transplantation benefits to treatment of glioblastoma (GBM) by enhancing anti-tumor effect in combination with GSK3β inhibitors and temozolomide (TMZ). We showed that MSCs co-cultured with GBM cells participate in regulation of GBM stem-like cell (SC) morphology. We examined the interaction between patient-derived GBM-SCs and adipose tissue-derived MSCs under GSK3β inhibition and TMZ and its influence on GBM-SCs. We found that combined treatment by GSK3β inhibitor enhanced therapeutic interaction of MSCs with GBM-SCs, and that combination of low-dose AR-A014418, TMZ and MSC treatment significantly reduced cell viability and showed anti-tumor effect against patient-derived GBM-SCs. Transplantation of MSCs and GSK3β inhibition improved survival in mouse GBM model.

Free Research Field

Neuro-oncology